A clinical trial at UCSF is testing a vaccine aimed at preventing cancer in individuals with Lynch syndrome, a genetic mutation that significantly increases the risk of colorectal and other cancers. Allen Rush, whose daughter died from Lynch-related colorectal cancer, is participating in the National Institutes of Health (NIH)-sponsored randomized, placebo-controlled study. Currently, surveillance through regular colonoscopies is the primary prevention strategy.
The vaccine trial seeks to stimulate the immune system to identify and eliminate abnormal cells before they develop into tumors.
Lynch Syndrome Overview
Lynch syndrome affects approximately 1 in 279 people in the U.S., with an estimated 95% unaware they carry the mutation. It significantly increases the lifetime risk of various cancers, including colorectal cancer. Early detection and adherence to screening recommendations are crucial for preventing or treating cancer at an early stage.
UCSF Lynch Syndrome Center
Launched in 2025, the UCSF Lynch Syndrome Center provides coordinated, multidisciplinary care for about 1,000 patients. It integrates specialists such as gastroenterologists, genetic counselors, gynecologists, dermatologists, and urologists.
The center also offers combined endometrial biopsies and colonoscopies under sedation, a service provided by only a few centers nationwide.
Additionally, it assists families in identifying relatives who may require genetic testing.
Advancements in Treatment
Beyond prevention, significant progress has been made in treating Lynch-related cancers. Immunotherapy has shown effectiveness, leading to complete remission in some advanced colorectal cancer cases.
Emerging research suggests certain Lynch-associated cancers might be treatable without surgery.